

Amendments to the Specification:

Please replace the Title at the top of page 1 with the following rewritten Title:

AGENTS THAT BIND TO AND INHIBIT HUMAN CYTOCHROME P450 ~~2C8, 2C9, 2C18~~
~~AND 2C19~~ 2C9*1, 2C9*2, and 2C9*3

Please replace the paragraph beginning at page 1, line 7, with the following rewritten paragraph:

This application is a divisional of U.S. Patent Application No. 09/469,655 filed December 22, 1999 (now U.S. Patent No. 6,623,960), which claims the benefit of U.S. Provisional Patent Application No. 60/119,972 filed February 12, 1999, the disclosures of which are incorporated by reference.

Please replace the paragraph beginning at page 27, line 5, with the following rewritten paragraph:

The specificity of binding of MAb 763-15-5 and MAb 763-15-20 to the expressed human P450 family members by ELISA ~~ELIZA~~ is shown in Figure 8. Figure 9 shows the specificity of MAb 763-15-5. MAb 763-15-5 inhibits each of the three 2C9 alleles catalyzed metabolism of one of the major 2C9 substrates. Phenanthrene metabolism was used for all P450s except diclofenac metabolism for the P450 2C9 alleles and bufuralol metabolism for P450 2D6. MAb 763-15-5 inhibited 2C9*2 by more than 90% and inhibited the P450 2C9*1 and 2C9*3 by more than 75%. MAb 763-15-20 inhibited 2C9*2 by more than 10% and did not exhibit significant inhibition of the P450 2C9*1 or 2C9*3.